AC Immune (ACIU) Competitors $2.94 +0.02 (+0.68%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ACIU vs. ANIP, CALT, BCAX, COGT, SEPN, COLL, GYRE, AVBP, AVDL, and NUVBShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include ANI Pharmaceuticals (ANIP), Calliditas Therapeutics AB (publ) (CALT), Bicara Therapeutics (BCAX), Cogent Biosciences (COGT), Septerna (SEPN), Collegium Pharmaceutical (COLL), Gyre Therapeutics (GYRE), ArriVent BioPharma (AVBP), Avadel Pharmaceuticals (AVDL), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. ANI Pharmaceuticals Calliditas Therapeutics AB (publ) Bicara Therapeutics Cogent Biosciences Septerna Collegium Pharmaceutical Gyre Therapeutics ArriVent BioPharma Avadel Pharmaceuticals Nuvation Bio AC Immune (NASDAQ:ACIU) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer ACIU or ANIP? ANI Pharmaceuticals received 176 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 64.58% of users gave ANI Pharmaceuticals an outperform vote while only 62.47% of users gave AC Immune an outperform vote. CompanyUnderperformOutperformAC ImmuneOutperform Votes25862.47% Underperform Votes15537.53% ANI PharmaceuticalsOutperform Votes43464.58% Underperform Votes23835.42% Do insiders and institutionals hold more shares of ACIU or ANIP? 51.4% of AC Immune shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ACIU or ANIP more profitable? AC Immune has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat AC Immune's return on equity.Company Net Margins Return on Equity Return on Assets AC ImmuneN/A -28.26% -18.98% ANI Pharmaceuticals -1.28%15.87%6.88% Do analysts prefer ACIU or ANIP? AC Immune presently has a consensus target price of $12.00, indicating a potential upside of 308.16%. ANI Pharmaceuticals has a consensus target price of $77.71, indicating a potential upside of 39.20%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings & valuation, ACIU or ANIP? ANI Pharmaceuticals has higher revenue and earnings than AC Immune. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$40.97M7.10-$60.41M-$0.46-6.39ANI Pharmaceuticals$555.46M2.11$18.78M-$0.55-101.51 Which has more risk and volatility, ACIU or ANIP? AC Immune has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Does the media prefer ACIU or ANIP? In the previous week, ANI Pharmaceuticals had 8 more articles in the media than AC Immune. MarketBeat recorded 10 mentions for ANI Pharmaceuticals and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.41 beat ANI Pharmaceuticals' score of 0.80 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryANI Pharmaceuticals beats AC Immune on 11 of the 18 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$290.88M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-6.3910.75135.1917.53Price / Sales7.10287.861,232.15140.37Price / CashN/A56.6540.6537.95Price / Book1.395.394.884.92Net Income-$60.41M$152.04M$118.97M$225.78M7 Day Performance-5.77%-4.32%15.41%-1.58%1 Month Performance-6.22%2.80%15.47%6.67%1 Year Performance-24.62%17.30%34.58%22.48% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.6607 of 5 stars$2.94+0.7%$12.00+308.2%-25.0%$290.88M$40.97M-6.39140Positive NewsANIPANI Pharmaceuticals4.8134 of 5 stars$57.68+1.2%$77.33+34.1%+5.5%$1.21B$486.82M0.00642Short Interest ↓CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180BCAXBicara TherapeuticsN/A$21.090.0%$43.00+103.9%N/A$1.15BN/A0.0032COGTCogent Biosciences2.265 of 5 stars$9.65+8.5%$14.83+53.7%+67.8%$1.07BN/A-3.9580Short Interest ↑High Trading VolumeSEPNSepterna1.7246 of 5 stars$23.62-8.3%$43.67+84.9%N/A$1.05BN/A0.00N/ACOLLCollegium Pharmaceutical3.9712 of 5 stars$30.99+3.4%$42.60+37.5%+4.3%$999.43M$566.77M12.92210News CoveragePositive NewsGYREGyre Therapeutics0.3745 of 5 stars$10.55-8.3%N/A-54.6%$986.64M$113.45M0.0040News CoverageGap UpHigh Trading VolumeAVBPArriVent BioPharma1.1728 of 5 stars$28.52-2.5%$36.80+29.0%N/A$961.12MN/A0.0040Short Interest ↑Positive NewsAVDLAvadel Pharmaceuticals2.7929 of 5 stars$9.96-0.4%$24.43+145.3%-23.3%$959.75M$27.96M0.00154Short Interest ↑NUVBNuvation Bio1.9366 of 5 stars$2.83-0.7%$6.60+133.2%+99.6%$952.49MN/A-1.3160 Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Bicara Therapeutics Competitors Cogent Biosciences Competitors Septerna Competitors Collegium Pharmaceutical Competitors Gyre Therapeutics Competitors ArriVent BioPharma Competitors Avadel Pharmaceuticals Competitors Nuvation Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACIU) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACIU Stock Alerts